Labetalol in Hypertension During the Third Trimester of Pregnancy: Its Antihypertensive Effect and Pharmacokinetic‐Dynamic Analysis

The hypotensive effect, kinetics, and concentration‐response relationship of labetalol, a β‐ and α1‐adrenoceptor blocking drug, were studied in seven women with a moderate‐to‐severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1‐ to 2‐day hospitalization period) during the third trimester of pregnancy who received the oral twice‐daily doses of 150 to 450 mg. These dosages were individually selected by attaining a therapeutic goal of DBP ≤ 100 mm Hg or systolic blood pressure (SBP)/DBP reduction of > 30/15 mm Hg, as compared with the pretreatment value, at any time during the 12‐hour dosing interval for a 3‐ to 5‐day dosage escalation period. Labetalol concentrations in plasma were measured by a high‐performance liquid chromatography with fluorescence detection, and the plasma drug concentration‐response relationship was analyzed by a sigmoidal Emax model. Labetalol decreased significantly (P < 0.05 to 0.01) the pretreatment SBP/DBP (166.3 ± 5.2/110.3 ± 3.0 mm Hg, mean ± SEM) without any recognizable side‐effects during the twice‐daily dosing period in the mothers. Peaked concentrations occurred at 1 hour postdose in all patients. The elimination half‐lives ranged from 4.3 to 6.9 hours, and the apparent oral clearance from 31.9 to 73.3 mL/min/kg. The pharmacodynamic parameters (Emax and EC50) analyzed by the Emax model revealed a 3‐ to 5‐fold interindividual variability. The gestational ages at delivery ranged from 34 to 37 weeks, and the birth weights were < 2000 g in 6 of the 7 neonates. Four neonates developed respiratory distress syndrome after delivery, and one infant died of pulmonary hypoplasia 3 months later. The results indicate that 1) labetalol orally administered in a twice‐daily regimen as done in this study is an effective antihypertensive drug in women with hypertension during late pregnancy, and 2) interindividual variability in the kinetic factor (e.g., oral clearance) as well as that in the pharmacodynamic factor (e.g., EC50) appear to be related to the overall variability in the hypotensive responsiveness to the drug. However, whether labetalol and/or hypertension per se would have been related to the fetal outcome remains unanswered from the present study.

[1]  E. Amon,et al.  A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy , 1987, Obstetrics and gynecology.

[2]  N. Vlachakis,et al.  Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. , 1983, The American journal of medicine.

[3]  I. Macgillivray,et al.  The classification and definition of the hypertensive disorders of pregnancy. , 1988, American journal of obstetrics and gynecology.

[4]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[5]  N. Kaplan Hypertension with pregnancy and the pill , 1976 .

[6]  J. McNeil,et al.  Labetalol steady-state pharmacokinetics in hypertensive patients. , 1982, British journal of clinical pharmacology.

[7]  B. Sandström Antihypertensive treatment with the adrenergic beta-receptor blocker metoprolol during pregnancy. , 1978, Gynecologic investigation.

[8]  O. Ylikorkala,et al.  Labetalol Does Not Alter the Placental and Fetal Blood Flow or Maternal Prostanoids in Pre-Eclampsia , 1986 .

[9]  D. M. Humphreys,et al.  A controlled trial of hypotensive agents in hypertension in pregnancy. , 1968, Lancet.

[10]  C. Michael Use of labetalol in the treatment of severe hypertension during pregnancy. , 1979, British journal of clinical pharmacology.

[11]  E. Gallery,et al.  Hypertension in pregnant women , 1985, The Medical journal of Australia.

[12]  T. Ishizaki,et al.  Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects , 1988, Clinical pharmacology and therapeutics.

[13]  J. Wallin,et al.  Labetalol. Current research and therapeutic status. , 1983, Archives of internal medicine.

[14]  P. Rubin Beta blockers in pregnancy. , 1981, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[15]  S. Kennedy,et al.  Atenolol in essential hypertension during pregnancy. , 1990, BMJ.

[16]  P. Rubin,et al.  Beta blockers in pregnancy , 1987, British journal of obstetrics and gynaecology.

[17]  C. Redman,et al.  FETAL OUTCOME IN TRIAL OF ANTIHYPERTENSIVE TREATMENT IN PREGNANCY , 1976, The Lancet.

[18]  J. Reid,et al.  Labetalol disposition and concentration-effect relationships during pregnancy. , 1983, British journal of clinical pharmacology.

[19]  W. Frishman,et al.  Beta-adrenergic blockers in pregnancy. , 1988, American heart journal.

[20]  J. McNeil,et al.  Clinical Pharmacokinetics of Labetalol , 1984, Clinical pharmacokinetics.

[21]  C M Metzler,et al.  Prediction of blood levels after multiple doses from single-dose blood level data: data generated with two-compartment open model analyzed according to the one-compartment open model. , 1969, Journal of pharmaceutical sciences.

[22]  B. Sibai,et al.  A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term , 1987, Obstetrics and gynecology.

[23]  R. Willes,et al.  Action of several β‐adrenoceptor blocking drugs in the pregnant sheep and foetus , 1973, British journal of pharmacology.

[24]  M. Lindheimer,et al.  Fetal outcome in hypertensive disorders of pregnancy. , 1982, American journal of obstetrics and gynecology.

[25]  John G. Wagner,et al.  Model-Independent Linear Pharmacokinetics , 1976 .

[26]  E. M. Symonds,et al.  The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. , 1989, British journal of obstetrics and gynaecology.

[27]  C. Michael The evaluation of labetalol in the treatment of hypertension complicating pregnancy. , 1982, British journal of clinical pharmacology.

[28]  S. Lowe,et al.  The pharmacological management of hypertension in pregnancy , 1992, Journal of hypertension.

[29]  J. McNeil,et al.  Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. , 1979, British journal of clinical pharmacology.

[30]  D. Clark,et al.  PLACEBO-CONTROLLED TRIAL OF ATENOLOL IN TREATMENT OF PREGNANCY-ASSOCIATED HYPERTENSION , 1983, The Lancet.

[31]  R. Christianson,et al.  The impact of mean arterial pressure in the middle trimester upon the outcome of pregnancy. , 1976, American journal of obstetrics and gynecology.

[32]  N. Rutter,et al.  The effect of maternal labetalol on the newborn infant. , 1986, British journal of obstetrics and gynaecology.

[33]  C. Knott The Treatment of Hypertension in Pregnancy , 1991 .

[34]  B. Carter Labetalol (Trandate, Glaxo Inc.; Normodyne, Schering Corp.) , 1983 .

[35]  C. Sabin,et al.  Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927. , 1981, The Journal of pharmacology and experimental therapeutics.

[36]  S. Hunyor,et al.  Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. , 1979, British medical journal.